



ASX Release  
29 April 2021

ASX Code: MEM

## GRANTED U.S. PATENTS FURTHER STRENGTHENS MEM I.P. PORTFOLIO

Australian-based bio-separations company Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") is pleased to announce the successful granting of two additional U.S. patents by the U.S. Patent and Trademark Office (USPTO), bringing the total number of patents granted to 4.

The additional U.S. patents granted are as follows:

**1. Sperm separation by electrophoresis (U.S. Patent No. 10,946,346, issued on 16 March 2021)**

A method of using at least one physically cross-linked biocompatible polymeric membrane in the separation of sperm by electrophoresis

**2. Biocompatible polymeric membranes (U.S. Patent No. 10,962,537 issued on 30 March 2021)**

A method of using at least one physically cross-linked biocompatible polymeric membrane in the separation of one or more macromolecules and/or cells by electrophoresis.

Memphasys Executive Chairman Alison Coutts said:

*"We are delighted that the USPTO has granted these two U.S. patents which further strengthens Memphasys' comprehensive patent portfolio and supports our unique bioseparations technology. The Felix device uses a suite of novel technologies to enable the quick and gentle separation of high quality sperm from a semen sample for use in human IVF procedures. With the granting of these patents the Company can progress its activities with greater certainty in its intellectual property rights."*

Memphasys also owns several pending patent applications in Australia, Europe, the USA and various Asian countries and has sole licensing rights from the University of Newcastle on three further patents granted in Australia, the UK and the USA pertaining to sperm cell separation by electrophoresis.

In addition, Memphasys has registered FELIX as a trade mark for its 'Felix' sperm separation devices in Australia, the US, the EU and India. Trade mark applications for FELIX have also been filed in Canada, China and Japan.

**This announcement has been approved for release by the board of Memphasys Limited.**

**ENDS**

**For further information please contact:**

Alison Coutts  
Executive Chairman  
Memphasys Limited  
T: +61 2 8415 7300

David Tasker  
Managing Director  
Chapter One Advisors  
T: +0433 112 936

E: [alison.coutts@memphasys.com](mailto:alison.coutts@memphasys.com)

E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)

**About Memphasys:**

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Website: [www.memphasys.com](http://www.memphasys.com)